{"id": "article-36238_0", "title": "Methylprednisolone -- Continuing Education Activity", "content": "Methylprednisolone is an FDA-approved medication for the management and treatment of allergic conditions, arthritis, asthma exacerbations, long-term asthma maintenance, acute exacerbation of multiple sclerosis, and as an anti-inflammatory and immunosuppressive agent. It is in the systemic corticosteroid class of medications. This activity outlines the indications, action, and contraindications for methylprednisolone as a valuable agent in treating many endocrine, inflammatory, immunologic, hematologic, and respiratory disorders.", "contents": "Methylprednisolone -- Continuing Education Activity. Methylprednisolone is an FDA-approved medication for the management and treatment of allergic conditions, arthritis, asthma exacerbations, long-term asthma maintenance, acute exacerbation of multiple sclerosis, and as an anti-inflammatory and immunosuppressive agent. It is in the systemic corticosteroid class of medications. This activity outlines the indications, action, and contraindications for methylprednisolone as a valuable agent in treating many endocrine, inflammatory, immunologic, hematologic, and respiratory disorders."}
{"id": "article-36238_1", "title": "Methylprednisolone -- Continuing Education Activity", "content": "Objectives: Identify the mechanism of action of methylprednisolone. Describe the potential adverse effects for patients taking methylprednisolone. Review and select the appropriate monitoring for patients on methylprednisolone. Outline the importance of improving care coordination and communication amongst the interprofessional team to enhance care delivery and improve outcomes for patients receiving methylprednisolone. Access free multiple choice questions on this topic.", "contents": "Methylprednisolone -- Continuing Education Activity. Objectives: Identify the mechanism of action of methylprednisolone. Describe the potential adverse effects for patients taking methylprednisolone. Review and select the appropriate monitoring for patients on methylprednisolone. Outline the importance of improving care coordination and communication amongst the interprofessional team to enhance care delivery and improve outcomes for patients receiving methylprednisolone. Access free multiple choice questions on this topic."}
{"id": "article-36238_2", "title": "Methylprednisolone -- Indications", "content": "Methylprednisolone is a systemic synthetic corticosteroid, which, just as the naturally occurring glucocorticoids, exerts a wide range of physiologic effects. Clinical use of methylprednisolone is mainly due to its anti-inflammatory and immunosuppressive activity in the human body. Labeled indications of methylprednisolone subcategorize by its use in different organ systems:", "contents": "Methylprednisolone -- Indications. Methylprednisolone is a systemic synthetic corticosteroid, which, just as the naturally occurring glucocorticoids, exerts a wide range of physiologic effects. Clinical use of methylprednisolone is mainly due to its anti-inflammatory and immunosuppressive activity in the human body. Labeled indications of methylprednisolone subcategorize by its use in different organ systems:"}
{"id": "article-36238_3", "title": "Methylprednisolone -- Indications", "content": "In dermatology, it has utility in managing atopic dermatitis,\u00a0contact dermatitis,\u00a0pemphigus vulgaris, and foliaceus,\u00a0bullous pemphigus,\u00a0erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis. [1] [2] [3] [4]", "contents": "Methylprednisolone -- Indications. In dermatology, it has utility in managing atopic dermatitis,\u00a0contact dermatitis,\u00a0pemphigus vulgaris, and foliaceus,\u00a0bullous pemphigus,\u00a0erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis. [1] [2] [3] [4]"}
{"id": "article-36238_4", "title": "Methylprednisolone -- Indications", "content": "In endocrinology, it is used to manage congenital adrenal hyperplasia,\u00a0hypercalcemia associated with cancer,\u00a0and as a second-line treatment in conjunction with mineralocorticoids for primary or secondary adrenocortical insufficiency.", "contents": "Methylprednisolone -- Indications. In endocrinology, it is used to manage congenital adrenal hyperplasia,\u00a0hypercalcemia associated with cancer,\u00a0and as a second-line treatment in conjunction with mineralocorticoids for primary or secondary adrenocortical insufficiency."}
{"id": "article-36238_5", "title": "Methylprednisolone -- Indications", "content": "In gastroenterology, methylprednisolone's use is for acute exacerbations of inflammatory bowel disease. [5] [6] [5] [7]", "contents": "Methylprednisolone -- Indications. In gastroenterology, methylprednisolone's use is for acute exacerbations of inflammatory bowel disease. [5] [6] [5] [7]"}
{"id": "article-36238_6", "title": "Methylprednisolone -- Indications", "content": "In hematology, it serves to treat autoimmune hemolytic anemia,\u00a0congenital (erythroid) aplastic anemia,\u00a0and immune thrombocytopenia. [8] [9] [10]", "contents": "Methylprednisolone -- Indications. In hematology, it serves to treat autoimmune hemolytic anemia,\u00a0congenital (erythroid) aplastic anemia,\u00a0and immune thrombocytopenia. [8] [9] [10]"}
{"id": "article-36238_7", "title": "Methylprednisolone -- Indications", "content": "In neurology, it is the mainstay therapy in acute exacerbations of multiple sclerosis. [11]", "contents": "Methylprednisolone -- Indications. In neurology, it is the mainstay therapy in acute exacerbations of multiple sclerosis. [11]"}
{"id": "article-36238_8", "title": "Methylprednisolone -- Indications", "content": "In ophthalmology, it is a therapeutic choice in severe allergic and inflammatory processes of the eye and its adnexa, such as\u00a0uveitis, scleritis, chorioretinitis, iritis and iridocyclitis, keratitis, optic neuritis, retinal vasculitis, and allergic conjunctivitis,", "contents": "Methylprednisolone -- Indications. In ophthalmology, it is a therapeutic choice in severe allergic and inflammatory processes of the eye and its adnexa, such as\u00a0uveitis, scleritis, chorioretinitis, iritis and iridocyclitis, keratitis, optic neuritis, retinal vasculitis, and allergic conjunctivitis,"}
{"id": "article-36238_9", "title": "Methylprednisolone -- Indications", "content": "In nephrology, it is helpful in the management of nephrotic syndrome, idiopathic type,\u00a0or secondary to lupus nephritis. [12] [13] [14]", "contents": "Methylprednisolone -- Indications. In nephrology, it is helpful in the management of nephrotic syndrome, idiopathic type,\u00a0or secondary to lupus nephritis. [12] [13] [14]"}
{"id": "article-36238_10", "title": "Methylprednisolone -- Indications", "content": "In pulmonology, its indications include aspiration pneumonitis,\u00a0asthma,\u00a0chronic beryllium disease as an adjunct to antituberculous chemotherapy in disseminated pulmonary tuberculosis, eosinophilic pneumonia,\u00a0and symptomatic sarcoidosis. [15] [16] [17] [18]", "contents": "Methylprednisolone -- Indications. In pulmonology, its indications include aspiration pneumonitis,\u00a0asthma,\u00a0chronic beryllium disease as an adjunct to antituberculous chemotherapy in disseminated pulmonary tuberculosis, eosinophilic pneumonia,\u00a0and symptomatic sarcoidosis. [15] [16] [17] [18]"}
{"id": "article-36238_11", "title": "Methylprednisolone -- Indications", "content": "In rheumatology, it has indications for the management of acute rheumatic carditis,\u00a0acute gout,\u00a0ankylosing spondylitis,\u00a0dermatomyositis and polymyositis,\u00a0psoriatic arthritis,\u00a0and rheumatoid arthritis, including the juvenile type and systemic lupus erythematosus. [19] [20] [21] [22] [23] [24] [25]", "contents": "Methylprednisolone -- Indications. In rheumatology, it has indications for the management of acute rheumatic carditis,\u00a0acute gout,\u00a0ankylosing spondylitis,\u00a0dermatomyositis and polymyositis,\u00a0psoriatic arthritis,\u00a0and rheumatoid arthritis, including the juvenile type and systemic lupus erythematosus. [19] [20] [21] [22] [23] [24] [25]"}
{"id": "article-36238_12", "title": "Methylprednisolone -- Indications", "content": "Other miscellaneous labeled indications for methylprednisolone include: Intraarticular and soft tissue administration in acute gouty arthritis, acute and subacute bursitis, acute tenosynovitis, epicondylitis, and synovitis of osteoarthritis. [26] [27] Intralesional administration in alopecia areata,\u00a0discoid lupus erythematosus,\u00a0keloid disease,\u00a0and lichen planus. [28] [29] [30] [31] Off-label indications of methylprednisolone include:", "contents": "Methylprednisolone -- Indications. Other miscellaneous labeled indications for methylprednisolone include: Intraarticular and soft tissue administration in acute gouty arthritis, acute and subacute bursitis, acute tenosynovitis, epicondylitis, and synovitis of osteoarthritis. [26] [27] Intralesional administration in alopecia areata,\u00a0discoid lupus erythematosus,\u00a0keloid disease,\u00a0and lichen planus. [28] [29] [30] [31] Off-label indications of methylprednisolone include:"}
{"id": "article-36238_13", "title": "Methylprednisolone -- Indications", "content": "Adjunct therapy for acute spinal cord injury Moderate to severe acute distress respiratory syndrome and severe alcoholic hepatitis As a preventive agent in bronchiolitis obliterans syndrome Hormonal resuscitation in cadaveric organ recovery Treatment of acute cellular and antibody-mediated rejection in cardiac transplant Adjunct in the management of acute exacerbation of chronic obstructive pulmonary disease Severe/refractory nausea and vomiting of pregnancy Adjunct treatment of Pneumocystis pneumonia in HIV-infected patients As palliation alternative in castration-resistant metastatic prostate cancer", "contents": "Methylprednisolone -- Indications. Adjunct therapy for acute spinal cord injury Moderate to severe acute distress respiratory syndrome and severe alcoholic hepatitis As a preventive agent in bronchiolitis obliterans syndrome Hormonal resuscitation in cadaveric organ recovery Treatment of acute cellular and antibody-mediated rejection in cardiac transplant Adjunct in the management of acute exacerbation of chronic obstructive pulmonary disease Severe/refractory nausea and vomiting of pregnancy Adjunct treatment of Pneumocystis pneumonia in HIV-infected patients As palliation alternative in castration-resistant metastatic prostate cancer"}
{"id": "article-36238_14", "title": "Methylprednisolone -- Mechanism of Action", "content": "Methylprednisolone and its derivatives, methylprednisolone acetate succinate, and methylprednisolone sodium, are intermediate-acting, synthetic glucocorticoids. They are used mainly as anti-inflammatory or immunosuppressive agents. Methylprednisolone is five times more potent in its anti-inflammatory properties relative to hydrocortisone (cortisol), with minimal mineralocorticoid activities compared to the latter. [32]", "contents": "Methylprednisolone -- Mechanism of Action. Methylprednisolone and its derivatives, methylprednisolone acetate succinate, and methylprednisolone sodium, are intermediate-acting, synthetic glucocorticoids. They are used mainly as anti-inflammatory or immunosuppressive agents. Methylprednisolone is five times more potent in its anti-inflammatory properties relative to hydrocortisone (cortisol), with minimal mineralocorticoid activities compared to the latter. [32]"}
{"id": "article-36238_15", "title": "Methylprednisolone -- Mechanism of Action", "content": "Methylprednisolone diffuses passively across the cellular membrane and binds to the intracellular glucocorticoid receptor. This complex translocates into the nucleus, where it interacts with specific DNA sequences, resulting in either enhancement or suppression of transcription of particular genes. The methylprednisolone-glucocorticoid receptor complex binds and blocks promoter sites of proinflammatory genes, [33] promotes expression of anti-inflammatory gene products, [34] and inhibits the synthesis of inflammatory cytokines, mainly by blocking the function of transcription factors, such as nuclear factor-kappa-B (NF-kB). [35]", "contents": "Methylprednisolone -- Mechanism of Action. Methylprednisolone diffuses passively across the cellular membrane and binds to the intracellular glucocorticoid receptor. This complex translocates into the nucleus, where it interacts with specific DNA sequences, resulting in either enhancement or suppression of transcription of particular genes. The methylprednisolone-glucocorticoid receptor complex binds and blocks promoter sites of proinflammatory genes, [33] promotes expression of anti-inflammatory gene products, [34] and inhibits the synthesis of inflammatory cytokines, mainly by blocking the function of transcription factors, such as nuclear factor-kappa-B (NF-kB). [35]"}
{"id": "article-36238_16", "title": "Methylprednisolone -- Mechanism of Action", "content": "Like the rest of the corticosteroids, methylprednisolone also suppresses the synthesis of cyclooxygenase (COX)-2, responsible for the production of prostaglandins in damaged tissue leading to the inflammation cascade. [36]", "contents": "Methylprednisolone -- Mechanism of Action. Like the rest of the corticosteroids, methylprednisolone also suppresses the synthesis of cyclooxygenase (COX)-2, responsible for the production of prostaglandins in damaged tissue leading to the inflammation cascade. [36]"}
{"id": "article-36238_17", "title": "Methylprednisolone -- Mechanism of Action", "content": "By reversing capillary permeability, suppressing the migration of fibroblasts and polymorphonuclear leukocytes, controlling the rate of protein synthesis, and stabilizing lysosomes at the cellular level, methylprednisolone may control or prevent inflammation through these actions as well.", "contents": "Methylprednisolone -- Mechanism of Action. By reversing capillary permeability, suppressing the migration of fibroblasts and polymorphonuclear leukocytes, controlling the rate of protein synthesis, and stabilizing lysosomes at the cellular level, methylprednisolone may control or prevent inflammation through these actions as well."}
{"id": "article-36238_18", "title": "Methylprednisolone -- Mechanism of Action", "content": "Methylprednisolone inhibits cell-mediated immunologic functions, especially those dependent on lymphocytes. Glucocorticoid administration results in neutrophilic leukocytosis, smaller elevations in monocytes, dramatic reductions in circulating eosinophils, and lesser reductions in lymphocytes. The use of methylprednisolone and other glucocorticoids results in a reduced ability of leukocytes to adhere to vascular endothelium and exit from the circulation. Glucocorticoids impair a variety of T cell functions, and moderate-to-high doses induce T cell apoptosis while keeping B cell function and antibody production preserved. [37]", "contents": "Methylprednisolone -- Mechanism of Action. Methylprednisolone inhibits cell-mediated immunologic functions, especially those dependent on lymphocytes. Glucocorticoid administration results in neutrophilic leukocytosis, smaller elevations in monocytes, dramatic reductions in circulating eosinophils, and lesser reductions in lymphocytes. The use of methylprednisolone and other glucocorticoids results in a reduced ability of leukocytes to adhere to vascular endothelium and exit from the circulation. Glucocorticoids impair a variety of T cell functions, and moderate-to-high doses induce T cell apoptosis while keeping B cell function and antibody production preserved. [37]"}
{"id": "article-36238_19", "title": "Methylprednisolone -- Mechanism of Action", "content": "Tissue-specific responses to steroids can occur by the presence in each tissue of specific protein regulators controlling the interaction between the hormone-receptor complex and particular DNA response elements. This activity leads to a wide array of gene expression and physiological responses by corticosteroids.", "contents": "Methylprednisolone -- Mechanism of Action. Tissue-specific responses to steroids can occur by the presence in each tissue of specific protein regulators controlling the interaction between the hormone-receptor complex and particular DNA response elements. This activity leads to a wide array of gene expression and physiological responses by corticosteroids."}
{"id": "article-36238_20", "title": "Methylprednisolone -- Mechanism of Action", "content": "Some of the most important effects of methylprednisolone and the rest of the corticosteroids are the result of homeostatic responses by insulin and glucagon. Glucocorticoids stimulate gluconeogenesis, which results in elevated blood glucose, catabolism of muscle protein, and stimulation of insulin secretion. Both lipolysis and lipogenesis become stimulated, with a net increase of fat deposition in certain areas (e.g., face, shoulders, and back). [38]", "contents": "Methylprednisolone -- Mechanism of Action. Some of the most important effects of methylprednisolone and the rest of the corticosteroids are the result of homeostatic responses by insulin and glucagon. Glucocorticoids stimulate gluconeogenesis, which results in elevated blood glucose, catabolism of muscle protein, and stimulation of insulin secretion. Both lipolysis and lipogenesis become stimulated, with a net increase of fat deposition in certain areas (e.g., face, shoulders, and back). [38]"}
{"id": "article-36238_21", "title": "Methylprednisolone -- Mechanism of Action", "content": "Methylprednisolone and the rest of the glucocorticoids cause muscle protein catabolism. Also, lymphoid and connective tissue, fat, and skin undergo wasting under the influence of high concentrations of these steroids. Catabolic effects on the bone can lead to osteoporosis. In children, growth inhibition takes place.", "contents": "Methylprednisolone -- Mechanism of Action. Methylprednisolone and the rest of the glucocorticoids cause muscle protein catabolism. Also, lymphoid and connective tissue, fat, and skin undergo wasting under the influence of high concentrations of these steroids. Catabolic effects on the bone can lead to osteoporosis. In children, growth inhibition takes place."}
{"id": "article-36238_22", "title": "Methylprednisolone -- Administration", "content": "Methylprednisolone may be administered orally with food or milk to decrease gastrointestinal adverse effects. Administration may also be intramuscularly or intravenously. When administered intramuscularly (in the form of methylprednisolone acetate or succinate), the administration should not be into the deltoid muscle due to evidence of subcutaneous atrophy. Injections into the dermis should be avoided, and injection should not be into areas that have evidence of acute local infection.", "contents": "Methylprednisolone -- Administration. Methylprednisolone may be administered orally with food or milk to decrease gastrointestinal adverse effects. Administration may also be intramuscularly or intravenously. When administered intramuscularly (in the form of methylprednisolone acetate or succinate), the administration should not be into the deltoid muscle due to evidence of subcutaneous atrophy. Injections into the dermis should be avoided, and injection should not be into areas that have evidence of acute local infection."}
{"id": "article-36238_23", "title": "Methylprednisolone -- Administration", "content": "Intravenous administration of methylprednisolone (in the form of methylprednisolone succinate) is rate dependent upon the dose and severity of the condition. Most commonly, with intermittent infusion, methylprednisolone is administered over 15 to 60 minutes. The administration of large doses should be over at least 30 to 60 minutes. There are reports of hypotension, cardiac arrhythmias, and sudden death when methylprednisolone administration occurs under 30 minutes in doses greater than or equal to 250 mg. [39]", "contents": "Methylprednisolone -- Administration. Intravenous administration of methylprednisolone (in the form of methylprednisolone succinate) is rate dependent upon the dose and severity of the condition. Most commonly, with intermittent infusion, methylprednisolone is administered over 15 to 60 minutes. The administration of large doses should be over at least 30 to 60 minutes. There are reports of hypotension, cardiac arrhythmias, and sudden death when methylprednisolone administration occurs under 30 minutes in doses greater than or equal to 250 mg. [39]"}
{"id": "article-36238_24", "title": "Methylprednisolone -- Administration", "content": "The onset of action of intravenous methylprednisolone succinate is within 1 hour, while intra-articular administration of methylprednisone acetate is of 1 week, with a duration of 1 to 5 weeks. Methylprednisolone has an oral bioavailability of 88% approximately. The half-life elimination of intravenous methylprednisolone is of 0.25 hours, with an oral half-life of 2-5 hours. It has hepatic metabolism and undergoes urinary excretion. [40] [41]", "contents": "Methylprednisolone -- Administration. The onset of action of intravenous methylprednisolone succinate is within 1 hour, while intra-articular administration of methylprednisone acetate is of 1 week, with a duration of 1 to 5 weeks. Methylprednisolone has an oral bioavailability of 88% approximately. The half-life elimination of intravenous methylprednisolone is of 0.25 hours, with an oral half-life of 2-5 hours. It has hepatic metabolism and undergoes urinary excretion. [40] [41]"}
{"id": "article-36238_25", "title": "Methylprednisolone -- Adverse Effects", "content": "The significant undesirable effects of glucocorticoids result from their hormonal actions, which lead to the clinical picture of iatrogenic Cushing syndrome. Facial rounding, puffiness, fat deposition, and plethora usually appear (moon facies). Fat tends to redistribute from the extremities to the trunk, the back of the neck, and the supraclavicular fossae. There is increased growth of fine hair on the face, thighs, and trunk. Steroid-induced punctate acne may appear, and insomnia and increased appetite are also effects.", "contents": "Methylprednisolone -- Adverse Effects. The significant undesirable effects of glucocorticoids result from their hormonal actions, which lead to the clinical picture of iatrogenic Cushing syndrome. Facial rounding, puffiness, fat deposition, and plethora usually appear (moon facies). Fat tends to redistribute from the extremities to the trunk, the back of the neck, and the supraclavicular fossae. There is increased growth of fine hair on the face, thighs, and trunk. Steroid-induced punctate acne may appear, and insomnia and increased appetite are also effects."}
{"id": "article-36238_26", "title": "Methylprednisolone -- Adverse Effects", "content": "With concurrent use of methylprednisolone, protein catabolism will continue, diverting amino acids to glucose production, thus increasing the need for insulin and over time resulting in weight gain. Myopathy and muscle wasting can occur, as well as thinning of the skin, with striae and bruising. Hyperglycemia and eventually osteoporosis can develop, as well as diabetes and aseptic necrosis of the hip. [42] A more detailed way to review the adverse effects of methylprednisolone and other corticosteroids is by classifying them based on the different organ systems affected:", "contents": "Methylprednisolone -- Adverse Effects. With concurrent use of methylprednisolone, protein catabolism will continue, diverting amino acids to glucose production, thus increasing the need for insulin and over time resulting in weight gain. Myopathy and muscle wasting can occur, as well as thinning of the skin, with striae and bruising. Hyperglycemia and eventually osteoporosis can develop, as well as diabetes and aseptic necrosis of the hip. [42] A more detailed way to review the adverse effects of methylprednisolone and other corticosteroids is by classifying them based on the different organ systems affected:"}
{"id": "article-36238_27", "title": "Methylprednisolone -- Adverse Effects", "content": "Dermatologic and side effects in appearance include skin thinning and ecchymoses, Cushingoid features, and weight gain. Ophthalmologic side effects include the formation of cataracts, increased intraocular pressure, and the development of exophthalmos. Cardiovascular side effects include fluid retention and hypertension, premature atherosclerotic disease, arrhythmias, and possible hyperlipidemia. Gastrointestinal effects include the increased risk of gastritis, ulcer formation, and gastrointestinal bleeding. Bone and muscle effects include osteoporosis, osteonecrosis, and myopathy. Neuropsychiatric side effects include mood disorders, psychosis, and memory impairment. Metabolic and endocrine side effects consist of hyperglycemia and hypothalamic-pituitary-adrenal axis suppression. Immune system effects include increased susceptibility to infections. Hematologic side effects include leukocytosis and neutrophilia.", "contents": "Methylprednisolone -- Adverse Effects. Dermatologic and side effects in appearance include skin thinning and ecchymoses, Cushingoid features, and weight gain. Ophthalmologic side effects include the formation of cataracts, increased intraocular pressure, and the development of exophthalmos. Cardiovascular side effects include fluid retention and hypertension, premature atherosclerotic disease, arrhythmias, and possible hyperlipidemia. Gastrointestinal effects include the increased risk of gastritis, ulcer formation, and gastrointestinal bleeding. Bone and muscle effects include osteoporosis, osteonecrosis, and myopathy. Neuropsychiatric side effects include mood disorders, psychosis, and memory impairment. Metabolic and endocrine side effects consist of hyperglycemia and hypothalamic-pituitary-adrenal axis suppression. Immune system effects include increased susceptibility to infections. Hematologic side effects include leukocytosis and neutrophilia."}
{"id": "article-36238_28", "title": "Methylprednisolone -- Contraindications", "content": "Methylprednisolone contraindications include patients with documented hypersensitivity to the drug or components, systemic fungal infection, intrathecal administration, live or attenuated virus vaccine, idiopathic thrombocytopenic purpura, or in premature infants. [43]", "contents": "Methylprednisolone -- Contraindications. Methylprednisolone contraindications include patients with documented hypersensitivity to the drug or components, systemic fungal infection, intrathecal administration, live or attenuated virus vaccine, idiopathic thrombocytopenic purpura, or in premature infants. [43]"}
{"id": "article-36238_29", "title": "Methylprednisolone -- Contraindications", "content": "Like all other glucocorticoids, methylprednisolone must be used with great caution in patients with peptic ulcers, heart disease or hypertension with heart failure, certain infectious illnesses such as varicella and tuberculosis psychoses, diabetes, osteoporosis, or glaucoma. [44]", "contents": "Methylprednisolone -- Contraindications. Like all other glucocorticoids, methylprednisolone must be used with great caution in patients with peptic ulcers, heart disease or hypertension with heart failure, certain infectious illnesses such as varicella and tuberculosis psychoses, diabetes, osteoporosis, or glaucoma. [44]"}
{"id": "article-36238_30", "title": "Methylprednisolone -- Monitoring", "content": "Blood pressure, blood glucose, electrolytes, weight, bone mineral density, HPA\u00a0hypothalamic-pituitary-adrenal\u00a0(HPA) axis suppression, and intraocular pressure all require monitoring in patients taking methylprednisolone. Growth and development monitoring should be in place for children.", "contents": "Methylprednisolone -- Monitoring. Blood pressure, blood glucose, electrolytes, weight, bone mineral density, HPA\u00a0hypothalamic-pituitary-adrenal\u00a0(HPA) axis suppression, and intraocular pressure all require monitoring in patients taking methylprednisolone. Growth and development monitoring should be in place for children."}
{"id": "article-36238_31", "title": "Methylprednisolone -- Monitoring", "content": "Patients receiving methylprednisolone must be monitored carefully for the development of hyperglycemia, glycosuria, sodium retention with edema or hypertension, hypokalemia, peptic ulcers, osteoporosis, and hidden infections.", "contents": "Methylprednisolone -- Monitoring. Patients receiving methylprednisolone must be monitored carefully for the development of hyperglycemia, glycosuria, sodium retention with edema or hypertension, hypokalemia, peptic ulcers, osteoporosis, and hidden infections."}
{"id": "article-36238_32", "title": "Methylprednisolone -- Monitoring", "content": "The dosage should be as low as possible. Even patients maintained on low doses of methylprednisolone may require supplementary therapy at times of stress, such as during surgery, intercurrent illness, or trauma occurs.", "contents": "Methylprednisolone -- Monitoring. The dosage should be as low as possible. Even patients maintained on low doses of methylprednisolone may require supplementary therapy at times of stress, such as during surgery, intercurrent illness, or trauma occurs."}
{"id": "article-36238_33", "title": "Methylprednisolone -- Toxicity", "content": "Most of the toxic effects of methylprednisolone and other glucocorticoids are predictable from their impact on the body's physiology. Some are life-threatening and include metabolic effects (growth inhibition, diabetes, muscle wasting, osteoporosis), salt retention (although less common with methylprednisolone), and psychosis.", "contents": "Methylprednisolone -- Toxicity. Most of the toxic effects of methylprednisolone and other glucocorticoids are predictable from their impact on the body's physiology. Some are life-threatening and include metabolic effects (growth inhibition, diabetes, muscle wasting, osteoporosis), salt retention (although less common with methylprednisolone), and psychosis."}
{"id": "article-36238_34", "title": "Methylprednisolone -- Toxicity", "content": "Methods for minimizing these toxicities include local application, alternate-day therapy (to reduce pituitary suppression), and tapering the dose promptly after attaining a therapeutic response. Additional \"stress doses\" may be necessary during serious illness or before major surgery to prevent adrenal insufficiency in patients who have received long-term treatment with methylprednisolone.", "contents": "Methylprednisolone -- Toxicity. Methods for minimizing these toxicities include local application, alternate-day therapy (to reduce pituitary suppression), and tapering the dose promptly after attaining a therapeutic response. Additional \"stress doses\" may be necessary during serious illness or before major surgery to prevent adrenal insufficiency in patients who have received long-term treatment with methylprednisolone."}
{"id": "article-36238_35", "title": "Methylprednisolone -- Enhancing Healthcare Team Outcomes", "content": "Methylprednisolone is a widely-used drug in multiple fields of medicine, mainly due to its anti-inflammatory and immunosuppressive properties. Interprofessional healthcare team members, including nurses, pharmacists, mid-level practitioners, and clinicians, should be aware of its broad spectrum of clinical applications, both labeled and off-labeled indications while considering its contraindications and individualizing its use based on the patient's comorbidities and tolerance of side effects. Of particular importance, patients receiving methylprednisolone should undergo monitoring for the development of hyperglycemia, hypertension, peptic ulcer, osteoporosis, and hidden infections.", "contents": "Methylprednisolone -- Enhancing Healthcare Team Outcomes. Methylprednisolone is a widely-used drug in multiple fields of medicine, mainly due to its anti-inflammatory and immunosuppressive properties. Interprofessional healthcare team members, including nurses, pharmacists, mid-level practitioners, and clinicians, should be aware of its broad spectrum of clinical applications, both labeled and off-labeled indications while considering its contraindications and individualizing its use based on the patient's comorbidities and tolerance of side effects. Of particular importance, patients receiving methylprednisolone should undergo monitoring for the development of hyperglycemia, hypertension, peptic ulcer, osteoporosis, and hidden infections."}
{"id": "article-36238_36", "title": "Methylprednisolone -- Enhancing Healthcare Team Outcomes", "content": "Clinicians (MDs, DOs, NPs, PAs) will be prescribing or ordering the medication. Nursing will administer if inpatient and can monitor for adverse effects in both inpatient and outpatient settings. Pharmacists should be involved to verify dosing and perform medication reconciliation. Both pharmacists and nurses need to alert the healthcare team if they encounter any issues of concern. All these interprofessional healthcare team members need to communicate and collaborate across interprofessional lines to ensure optimal therapeutic results. [Level 5]", "contents": "Methylprednisolone -- Enhancing Healthcare Team Outcomes. Clinicians (MDs, DOs, NPs, PAs) will be prescribing or ordering the medication. Nursing will administer if inpatient and can monitor for adverse effects in both inpatient and outpatient settings. Pharmacists should be involved to verify dosing and perform medication reconciliation. Both pharmacists and nurses need to alert the healthcare team if they encounter any issues of concern. All these interprofessional healthcare team members need to communicate and collaborate across interprofessional lines to ensure optimal therapeutic results. [Level 5]"}
{"id": "article-36238_37", "title": "Methylprednisolone -- Enhancing Healthcare Team Outcomes", "content": "As with all glucocorticoids, methylprednisolone's adverse effects are both dose- and duration-dependent and can range from non-serious displeasing appearance to those that are life-threatening. Interprofessional coordination and care between healthcare workers are needed to ensure that methylprednisolone dosage remains minimal and for the shortest period necessary to achieve the treatment goals. Preexisting comorbidities that may become exacerbated when treated with methylprednisolone require management, and that patients under treatment should be monitored by the pharmacist, nurse, and clinician for adverse effects, identifying who may benefit from additional intervention. An interprofessional team approach will lead to the best outcomes. [Level 5]", "contents": "Methylprednisolone -- Enhancing Healthcare Team Outcomes. As with all glucocorticoids, methylprednisolone's adverse effects are both dose- and duration-dependent and can range from non-serious displeasing appearance to those that are life-threatening. Interprofessional coordination and care between healthcare workers are needed to ensure that methylprednisolone dosage remains minimal and for the shortest period necessary to achieve the treatment goals. Preexisting comorbidities that may become exacerbated when treated with methylprednisolone require management, and that patients under treatment should be monitored by the pharmacist, nurse, and clinician for adverse effects, identifying who may benefit from additional intervention. An interprofessional team approach will lead to the best outcomes. [Level 5]"}
{"id": "article-36238_38", "title": "Methylprednisolone -- Review Questions", "content": "Access free multiple choice questions on this topic. Comment on this article.", "contents": "Methylprednisolone -- Review Questions. Access free multiple choice questions on this topic. Comment on this article."}